selected publications
-
Tumor cell heterogeneity and resistance; report from the 2018 Coffey-Holden Prostate Cancer Academy Meeting.
The Prostate.
2018
Information Resource
GET IT
Times cited: 8 -
Microsatellite Instability Is Associated With the Presence of Lynch Syndrome Pan-Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 414 -
Prevalence of Germline Mutations in Cancer Susceptibility Genes in Patients With Advanced Renal Cell Carcinoma.
JAMA oncology.
2018
Academic Article
GET IT
Times cited: 126 -
Germline SDHA mutations in children and adults with cancer.
Cold Spring Harbor molecular case studies.
2018
Academic Article
GET IT
Times cited: 34 -
Alterations in DNA Damage Response and Repair Genes as Potential Marker of Clinical Benefit From PD-1/PD-L1 Blockade in Advanced Urothelial Cancers.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2018
Academic Article
GET IT
Times cited: 404 -
Characterizing recurrent and lethal small renal masses in clear cell renal cell carcinoma using recurrent somatic mutations.
Urologic oncology.
2017
Academic Article
GET IT
Times cited: 21 -
Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
European urology focus.
2017
Academic Article
GET IT
Times cited: 28 -
Characterization and Impact of TERT Promoter Region Mutations on Clinical Outcome in Renal Cell Carcinoma.
European urology focus.
2017
Academic Article
GET IT
Times cited: 38 -
Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing.
JAMA.
2017
Academic Article
GET IT
Times cited: 367 -
Genomic Characterization of Renal Medullary Carcinoma and Treatment Outcomes.
Clinical genitourinary cancer.
2017
Academic Article
GET IT
Times cited: 35 -
Genomic alterations as predictors of survival among patients within a combined cohort with clear cell renal cell carcinoma undergoing cytoreductive nephrectomy.
Urologic oncology.
2017
Academic Article
GET IT
Times cited: 22 -
Overcome tumor heterogeneity-imposed therapeutic barriers through convergent genomic biomarker discovery: A braided cancer river model of kidney cancer.
Seminars in cell & developmental biology.
2016
Information Resource
GET IT
Times cited: 38 -
Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.
Nature reviews. Urology.
2016
Review
GET IT
Times cited: 83 -
Response to Nivolumab in a Patient With Metastatic Clear Cell Renal Cell Carcinoma and End-stage Renal Disease on Dialysis.
European urology.
2016
Article
GET IT
Times cited: 33 -
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma.
The oncologist.
2016
Academic Article
GET IT
Times cited: 83